Introduction {#S1}
============

Since the introduction of prostate specific-antigen (PSA) screening, an increasing number of men are being diagnosed with low grade, low stage, small volume cancers that are potentially biologically indolent. Consequently, choosing whether and how to treat these tumors remains challenging. Men newly diagnosed with low-risk prostate cancer are frequently treated with standard therapies (i.e. radical prostatectomy, external beam radiation therapy (EBRT), brachytherapy, androgen deprivation therapy (ADT), or conservative management), \[[@R1]\], which are associated with high overall, cancer-specific, and biochemical-recurrence free survival. However, radical prostatectomy, radiation therapy, and ADT are accompanied by side effects (e.g. bladder and bowel dysfunction) that may impact negatively on health related quality of life. Conversely, conservative management may induce anxiety and elevate stress levels \[[@R2]\]. As such, renewed interest has emerged in utilizing minimally invasive approaches, such as cryotherapy, to treat men diagnosed with clinically, localized prostate cancer.

Cryotherapy has become more widespread in practice due to a better understanding of cryobiology \[[@R3]\], introduction of third-generation cryoprobes, and improvements in biopsy and imaging techniques, which have enhanced the ability to map the foci and location of tumors within the prostate and subsequently reduce morbidity while improving effectiveness \[[@R3]--[@R5]\].

Although cryotherapy has been identified as a potential treatment option for men with clinically organ-confined disease by the American Urological Association, \[[@R3]\] there is no formal definition of cryotherapy eligible tumors and a lack of information regarding the actual recipients of cryotherapy. Moreover, morbidity associated with cryotherapy has been primarily reported from single hospital-based studies, typically in highly selected patients \[[@R6]--[@R14]\]. Thus, in a population-based study, we identify the risk profile of men with clinically localized prostate cancer initially treated with cryotherapy and characterize post treatment-related complications.

Material and Methods {#S2}
====================

Data for this study was obtained from the 16 tumor registries participating in the National Cancer Institute's Surveillance Epidemiology Ends Results (SEER) program database linked to Medicare administrative claims. The SEER program monitors approximately 26% of the United States population and has complete ascertainment in 98% of cases \[[@R15]\]. Our study cohort consisted of men ≥66 years diagnosed with incident, localized prostate cancer (ICD-O-3 site code C619) while enrolled in Medicare between 2004 and 2005. All patients were initially treated with cryotherapy, a form of aggressive standard therapy (i.e. radical prostatectomy or radiation therapy) or non-aggressive standard therapy (ADT or conservative management) within one year of being diagnosed with prostate cancer. Men with advanced prostate cancer (T3 or T4) (n = 2,519) or prior cancers (n = 4,896) were excluded. Additional exclusion criteria included patients whose diagnosis of prostate cancer was obtained from autopsy or death certificate (n=745) or tumor pathology not consistent with adenocarcinoma (n =2,167). Given that transurethral resection of the prostate (TURP) increases the risk of urinary complications, men with a history of TURP (n =32) or those who underwent TURP in combination with cryotherapy (n = 191) were excluded \[[@R16]\]. Men with unknown Gleason score (n=1,120), PSA level (n =4,589), clinical stage (n=1,249), or covariates (n = 52) were also excluded. The final study cohort consisted of 21,344 men newly diagnosed with localized prostate cancer.

Treatment {#S3}
---------

Cryotherapy and standard therapies were administered within one year following initial diagnosis of prostate cancer. Cryotherapy was identified from Medicare inpatient and outpatient claims using International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) procedure code 60.62, Current Procedural Terminology (CPT) code 55873, Health Care Financing Administration Common Procedure Coding System (HCPCS) codes G0160 and G0161, and SEER data. Standard forms of therapy were identified from Medicare billing codes and SEER data.

Complications {#S4}
-------------

ICD-9/CPT/HCPCS codes and Medicare claims data were utilized to ascertain the prevalence of diagnoses and invasive procedures reported for urinary, bowel, and sexual function related complications occurring three, six, and twelve-months after cryotherapy. Patients with a Medicare claim of urinary, rectal, or erectile dysfunction diagnoses or procedural related complications prior to cryotherapy were excluded in order to identify the prevalence of post-treatment complications, which included lower urinary tract obstruction, erectile dysfunction, urinary incontinence, bowel bleeding, hydronephrosis, urinary fistula, and bowel fistula. The medical codes for diagnoses and procedures for the aforementioned complications are provided in Appendix A.

Covariates {#S5}
----------

Demographic variables included age, race, marital status, income, geographic region, PSA, Gleason score, clinical stage, cancer recurrence risk level, and Charlson co-morbidity. Charlson co-morbidity score was derived from Medicare claims during the year prior to prostate cancer diagnosis by using a validated algorithm \[[@R17]\]. Risk level, a measure of disease progression and PSA failure, was defined based on the risk model defined by the National Comprehensive Cancer Network \[[@R17]\]. Low risk included clinical stage ≤ T2a, PSA level ≤ 10 ng/ml, Gleason score ≤ 6; intermediate risk included clinical stage T2b--T2c, PSA \> 10 and ≤ 20 ng/ml, Gleason score = 7; and high risk included PSA \> 20 ng/ml, Gleason score ≥ 8 \[[@R18]\].

Statistical analysis {#S6}
--------------------

Multivariate logistic regression was utilized to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association between patient and tumor characteristics and the selection of cryotherapy as opposed to aggressive or nonaggressive standard forms of therapy. Rates of urinary, bowel, and sexual function related diagnoses and corrective invasive procedures occurring three, six, and twelve months following cryotherapy are presented. All analyses were performed using SAS statistical software (version 9.1, SAS Institute, Cary, NC). The study was approved by the University of Medicine and Dentistry of New Jersey Institutional Review Board.

Results {#S7}
=======

A total of 380 patients (1.8%) underwent cryotherapy as initial treatment for localized prostate cancer and had at least one year of follow-up after cryotherapy. The majority of participants treated with cryotherapy, radical prostatectomy, or radiation therapy were 66--74 years, 61.3%, 92.2%, and 62.6%, respectively, whereas the majority of men given ADT or conservative management were ≥75 years, 68.8% and 54.4%, respectively. Most men treated with cryotherapy were diagnosed as having intermediate-risk disease (50%), followed by low-risk (33.7%) and high-risk (16.1%) disease. Of cryotherapy patients, 70.5% had no co-morbidities, 22.1% had one co-morbidity, and 7.4% had at least two co-morbidities.

In multivariate analyses, age, marital status, income, geographic region, Gleason score, and Charlson co-morbidity score were significantly related to the selection of cryotherapy over aggressive therapies as initial treatment ([Table 2](#T2){ref-type="table"}). For instance, men ≥75 years were 1.58 (95% CI: 1.27, 1.95) times as likely to have cryotherapy than men 66--74 years. Income was inversely associated with the use of cryotherapy, such that men from low income were 1.46 (95% CI: 1.10, 1.93) times as likely to receive cryotherapy than men from higher income. Gleason score was the only tumor-related characteristic that was associated with cryotherapy use.

High-risk patients were less likely to be treated with cryotherapy than low-risk patients (OR = 0.70; 95% CI: 0.51, 0.96) ([Table 3](#T3){ref-type="table"}). The use of cryotherapy did not vary between men with intermediate or low-risk disease (OR = 1.00; 95% CI: 0.80, 1.26).

Within three months after undergoing cryotherapy, 23.7% of men were diagnosed with or treated for lower urinary tract obstruction ([Table 4](#T4){ref-type="table"}). Erectile dysfunction, urinary incontinence, and bowel bleeding were prevalent in 4.0%, 3.8%, and \<2.9% of men, respectively. By six months, the rate of erectile dysfunction more than tripled and urinary incontinence doubled. Twelve months following cryotherapy, lower urinary tract obstruction, erectile dysfunction, urinary incontinence, and bowel bleeding rose to 28.7%, 20.1%, 9.8%, and 3.3% respectively. No man had a diagnosis or corrective invasive procedure within twelve months following cryotherapy for hydronephrosis, urinary fistula, or bowel fistula.

Of the patients diagnosed with urinary incontinence, no one had a corrective invasive procedure, \<11 of men had a procedure to alleviate lower urinary tract obstruction or to ameliorate erectile dysfunction.

Discussion {#S8}
==========

In this population-based study, we found that cryotherapy remains a novel strategy to treat men initially diagnosed with clinically localized prostate cancer. We observed that besides disease-risk level that several demographic characteristics are significantly associated with receiving cryotherapy. In addition, among men with no prior history of treatment-related complications, the rates of urinary incontinence, hydronephrosis, bowel bleeding, urinary fistula, and bowel fistula post treatment were minimal. However, the rates of lower urinary tract obstruction and erectile dysfunction are common, but there is little need for ancillary corrective, invasive procedures.

Although, men with high-risk disease were significantly less likely to receive cryotherapy than men with low-risk disease, nearly one in five men administered cryotherapy had high-risk disease (16.1%), indicating that in clinical practice cryotherapy is being used in patients with more aggressive cancers, (i.e. men with PSA levels \>20ng/ml or Gleason score 8--10). Albeit selection criteria for men undergoing prostate cryotherapy have yet to be definitively established, optimal candidates for this procedure generally include those with lower stage, lower volume disease with PSA levels \<20 ng/ml \[[@R19]\].

Interestingly, an inverse association between income and cryotherapy was observed. This may indicate that cryotherapy is becoming an attractive alternative for men with lesser means possibly in part because it is associated with shorter hospital stay, faster recovery time, and is theoretically less costly than standard therapy \[[@R20]\]. Our findings support past studies, which have demonstrated that men with lower socioeconomic status were less likely to receive aggressive therapy in comparison to their richer counterparts \[[@R21]\]. For example, Cooperberg et al. recently reported that a greater percentage of men with an annual income of \<\$20,000, \$20,000--\$30,000, or \$30,00--\$50,000 were treated with cryotherapy than men with an annual income ≥\$50,000 \[[@R22]\].

Of particular significance in our study, is the finding that the proportion of patients developing erectile dysfunction or urinary incontinence may increase over time, suggesting that the effects of cryotherapy may not only arise immediately after cryotherapy, but remotely as well. For instance, from six months to twelve months following treatment, the rates of erectile dysfunction increased from 13.2% to 20.1% and urinary incontinence rose from 7.9% to 9.8%.

Complications occurring after cryotherapy have been widely studied in small single hospital-based studies. Reports of urinary incontinence ranged from 1.3 to 9.5% \[[@R7],[@R9]--[@R12],[@R14], [@R23],[@R24], [@R25]\], urinary strictures from 1.7% to 3.4% \[[@R10],[@R12],[@R14]\], lower urinary tract obstruction/retention from 13% to 23% \[[@R24], [@R26]--[@R28]\], bowel bleeding was 2.0% \[[@R12]\], and erectile dysfunction from 47% to 94.9% \[[@R7],[@R10],[@R11],[@R14]\]. Consistently, cryotherapy was found to be associated with a low rate of fistulas (\<1%) several years after the procedure \[[@R7],[@R10]--[@R14]\]. In our cohort of men receiving prostate cryotherapy, no urinary or bowel fistulas or hydronephrosis were reported and bowel bleeding was observed to be low twelve months after cryotherapy. The twelve-month rates of lower urinary tract obstruction and urinary incontinence in this study were greater than reported in prior studies. The higher complication rates found in this study may reflect differences in the definition of the complications or the use of population-based data as opposed to hospital-based data. The twelve-month rates of lower urinary tract obstruction and urinary incontinence in this study were greater than reported in prior studies. The higher complication rates found in this study may reflect differences in the definition of the complications, the use of population-based data as opposed to hospital-based data, or publication bias. In particular, the higher rates of postoperative urinary incontinence may be indicative of the higher rates of mild to severe urinary symptoms in older men \[[@R29], [@R30]\] that often is underreported \[[@R30], [@R31]\], and a larger prostate volume \[[@R32]\] which interferes with urinary incontinence. Thus, the older men in this study may have some degree of pre-existing urinary dysfunction or larger prostate, which may augment their risk of urinary incontinence post cryotherapy. The rate of erectile dysfunction in this study was lower than previous estimates and may be attributed to our study population consisting of men 66 years of age or older. Older men may not be as concerned about reporting and treating erectile dysfunction as younger men. In addition, some cases of erectile dysfunction may not have been identified because we lacked validated instruments to assess erectile dysfunction such as the International Index of Erectile Function \[[@R33]\], the Quality of Erection Questionnaire \[[@R34]\], or the Sexual Health Inventory for Men \[[@R35]\]. It is also feasible that the rate of erectile dysfunction may have been underestimated during the study period because some patients may have used devices or agents (e.g. vacuum erection device, internal penile pump, phosphodiesterase type 5 inhibitors) to rectify their erectile dysfunction.

The postoperative complication rates may also vary across studies because of differences in tumor characteristics (e.g. gland size), rates of complications pre-cryotherapy (e.g. impotency), duration of follow-up, definition of complications, inclusion of men with a history of TURP, use of previous treatments (e.g. external beam radiation therapy), and the generation of the cryotherapy device(s).

An advantage of the present study is that updated data pertaining to cryotherapy was utilized. Previous studies reported outcomes when cryotechnology and imaging were evolving \[[@R7],[@R9]--[@R14],[@R23]\]. Since then, further technological advancements in the field have been achieved, such as the use of argon gas instead liquid nitrogen, which has enabled cryotherapy to be delivered in a more precise, safer, and efficacious manner \[[@R3], [@R36]\]. Consequently, our findings provide valuable insight into the prevalence of morbidity associated with this treatment in a technologically more advanced era.

Certain limitations of our study warrant mention. Although our findings likely reflect clinical practice in the United States because the SEER database covers 26% of the United States population, we were unable to explore the influence of other pertinent risk factors, such as gland volume and configurations. Additionally, given that the data for this study were extracted from administrative claims data, we were unable to evaluate erectile dysfunction and urinary complications using validated instruments of quality of life \[[@R33]--[@R35]\]. Thus, the rates of these complications may be underestimated. Further, due to the inherent limitations of using administrative claims data we were unable to decipher the generation of the cryotherapy devices that were performed on patients. However, given that the procedures occurred within a narrow window of time from 2004 to 2005, variation in the generation of the cryotherapy devices utilized was most likely minimized.

The results from this study may not be generalizable to younger men because Medicare consists of men 65 years and older. We also could not distinguish between whole gland cryotherapy and focal cryotherapy, as current procedural codes do not exist to allow for this differentiation. Finally, the use of administrative claims to estimate treatment-related complications may result in an underestimation of the true complication prevalence.

In summary, our findings provide an estimate of contemporary post-treatment complications associated with cryotherapy. The results from this study suggest that among men diagnosed with localized prostate cancer that morbidity post cryotherapy is modest; lower urinary tract obstruction and erectile dysfunction remain common following cryotherapy; complications can manifest even one year after treatment; and a small proportion of men may require invasive corrective procedures to address these complications. Patients should be fully informed of the complications presented herein as well as the lack of well-controlled or randomized studies supporting its efficacy.
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###### 

Characteristics of patients treated with cryotherapy and standard forms of therapy for incident localized prostate cancer, SEER-Medicare.

                                                                             Aggressive standard therapies   Non-aggressive standard therapies                          
  --------------------------------------------------- ---------------------- ------------------------------- ----------------------------------- ---------------------- --------------------
  **Age (yrs)**                                                                                                                                                         
    66--74                                            61.3                   92.2                            62.6                                31.2                   45.6
    75+                                               38.7                   7.8                             37.5                                68.8                   54.4
  **Race**                                                                                                                                                              
    White                                             81.1                   83.9                            82.2                                77.8                   78.3
    Black                                             12.1                   8.0                             10.4                                13.6                   14.7
    Other                                             6.8                    8.1                             7.4                                 8.7                    7.0
  [2](#TFN4){ref-type="table-fn"}**Marital Status**                                                                                                                     
    Married                                           66.8                   81.8                            75.0                                56.4                   57.3
    Unmarried                                         22.1                   14.5                            19.6                                23.0                   24.0
    Unspecified                                       11.1                   3.7                             5.3                                 20.7                   18.8
  **Income \$**                                       \$44,315               \$51,582                        \$49,526                            \$43,257               \$46,088
  Median (IQR)                                        (\$33,090, \$57,677)   (\$39,208, \$70,418)            (\$36,371, \$66,651)                (\$31,507, \$59,650)   (\$33,294, 63,501)
  **Region**                                                                                                                                                            
    South                                             32.4                   12.4                            17.4                                20.5                   18.1
    North Central                                     7.9                    12.6                            12.6                                11.8                   10.0
    Northeast                                         10.0                   10.4                            26.5                                17.8                   15.2
    West                                              49.7                   64.7                            43.5                                49.9                   56.7
  **PSA (ng/ml)**                                                                                                                                                       
    0--2.5                                            3.7                    5.7                             5.4                                 4.5                    6.3
    2.6--≤4.0                                         6.4                    8.4                             6.3                                 3.6                    6.3
    4.1--≤10                                          65.3                   66.8                            60.8                                36.8                   57.0
    10.1--19.9                                        16.6                   13.4                            18.2                                24.8                   17.5
    ≥ 20                                              8.2                    5.8                             9.3                                 30.3                   13.0
  **Gleason Score**                                                                                                                                                     
    2--6                                              46.1                   36.8                            48.5                                32.7                   64.3
    7                                                 44.2                   49.8                            36.7                                37.3                   24.8
    8--10                                             9.7                    13.4                            14.9                                30.0                   10.9
  **Clinical Stage**                                                                                                                                                    
    T1                                                50.5                   55.3                            57.1                                44.2                   52.7
    T2                                                49.5                   44.7                            42.9                                55.8                   47.3
  [3](#TFN5){ref-type="table-fn"}**Risk**                                                                                                                               
    Low                                               33.7                   28.1                            34.6                                17.7                   46.6
    Intermediate                                      50.3                   54.0                            44.2                                36.0                   34.4
    High                                              16.1                   18.0                            21.3                                46.3                   19.0
  **Charlson Co-morbidity Score**                                                                                                                                       
    0                                                 70.5                   84.0                            73.8                                66.1                   72.6
    1                                                 22.1                   12.8                            18.1                                20.6                   17.7
    2+                                                7.4                    3.2                             8.1                                 13.3                   9.8

IQR = Interquartile Range; ADT = Androgen Deprivation Therapy

Chi-square test used to assess the independence of patient demographic and clinical characteristics across treatment groups. All p-values were \<0.001.

Radiation therapy includes external beam radiation therapy and brachytherapy

Unmarried consists of men reported being separated, divorced, or widowed

Patients were categorized into three risk groups on the basis of clinical classification, PSA level and Gleason score: low-risk (T1--T2a and PSA level \<10 ng/mL and Gleason score 2--6), intermediate-risk (T2b--T2c or 10 ≤ PSA ≤ 20 ng/mL or Gleason score = 7) and high-risk (PSA level \>20ng/mL or Gleason score 8--10).

###### 

Adjusted[1](#TFN6){ref-type="table-fn"} Odds Ratios (95% Confidence Intervals) for factors associated with the selection of cryotherapy instead of aggressive standard therapy[2](#TFN7){ref-type="table-fn"} in men diagnosed with incident localized prostate cancer, SEER-Medicare.

  Characteristics                                     OR         95% CI         p-value
  --------------------------------------------------- ---------- -------------- ---------
  **Age (yrs)**                                                                 
    75+                                               1.58       (1.27, 1.95)   \<0.001
    66--74                                            Referent                  
  **Race**                                                                      
    Black/Other                                       0.99       (0.75, 1.29)   0.910
    White                                             Referent                  
  **Marital Status**[3](#TFN8){ref-type="table-fn"}                             
    Unmarried/Unspecified                             1.66       (1.33, 2.07)   \<0.001
    Married                                           Referent                  
  **Income**                                                                    
    Lowest Tertile                                    1.46       (1.10, 1.93)   0.008
    Middle Tertile                                    1.35       (1.03, 1.77)   0.031
    Highest Tertile                                   Referent                  
  **Region**                                                                    
    South                                             1.81       (1.42, 2.31)   \<0.001
    North Central                                     0.55       (0.37, 0.81)   0.003
    Northeast                                         0.45       (0.31, 0.64)   \<0.001
    West                                              Referent                  
  **PSA (ng/ml)**                                                               
    0.1--≤10                                          Referent                  
    10.1--19.9                                        0.92       (0.69, 1.21)   0.544
    ≥ 20                                              0.95       (0.65, 1.40)   0.805
  **Gleason Score**                                                             
    2--6                                              Referent                  
    7                                                 1.04       (0.84, 1.29)   0.732
    8--10                                             0.60       (0.41, 0.86)   0.006
  **Clinical stage**                                                            
    T2                                                1.22       (0.99, 1.50)   0.059
    T1                                                Referent                  
  **Charlson Co-Morbidity Score**                                               
    0                                                 Referent                  
    1                                                 1.41       (1.10, 1.81)   0.008
    2+                                                1.15       (0.77, 1.71)   0.498

Adjusted for patient and tumor characteristics included in the Table.

Aggressive standard therapies include radical prostatectomy, external beam radiation therapy, and brachytherapy.

Unmarried consists of men reported being separated, divorced, or widowed

###### 

The adjusted[1](#TFN9){ref-type="table-fn"} association between the selection of cryotherapy instead of aggressive[2](#TFN10){ref-type="table-fn"} standard therapies in men diagnosed with incident localized prostate cancer, SEER-Medicare.

  NCCN Criterion[3](#TFN11){ref-type="table-fn"}   OR         95% CI         p-value
  ------------------------------------------------ ---------- -------------- ---------
  High                                             0.70       (0.51, 0.96)   0.026
  Intermediate                                     1.00       (0.80, 1.26)   0.986
  Low                                              Referent                  

Adjusted for age, race, marital status, income, region, and Charlson Co-morbidity Score.

Aggressive standard therapies include radical prostatectomy, external beam radiation therapy, and brachytherapy.

Patients were categorized into three risk groups on the basis of clinical classification, PSA level and Gleason score: low-risk (T1--T2a and PSA level \<10 ng/mL and Gleason score 2--6), intermediate-risk (T2b--T2c or 10 ≤ PSA ≤ 20 ng/mL or Gleason score = 7) and high-risk (PSA level \>20ng/mL or Gleason score 8--10).

###### 

Combined diagnoses and procedural related complications reported 3, 6, and 12 months after cryotherapy in men diagnosed with incident localized prostate cancer and no prior history of treatment related morbidity, SEER-Medicare.

                                                                    3 months   6 months   12 months                
  ----------------------------------------------------------------- ---------- ---------- ----------- ------- ---- ------
  [1](#TFN12){ref-type="table-fn"}Lower Urinary Tract Obstruction   78         23.7       90          27.4    94   28.7
  [2](#TFN13){ref-type="table-fn"}Erectile Dysfunction              14         4          46          13.2    70   20.1
  [3](#TFN14){ref-type="table-fn"}Urinary Incontinence              14         3.8        29          7.9     36   9.8
  [4](#TFN15){ref-type="table-fn"}Bowel Bleeding                    \<11       \<2.9      \<11        \<2.9   12   3.3
  [5](#TFN16){ref-type="table-fn"}Hydronephrosis                    0          0          0           0       0    0
  [6](#TFN17){ref-type="table-fn"}Urinary Fistula                   0          0          0           0       0    0
  [7](#TFN18){ref-type="table-fn"}Bowel Fistula                     0          0          0           0       0    0

Lower Urinary Tract Obstruction included medical claim of dilation, urethrotomy, urethroplasty, sphincterotomy; transurethral prostate resection/destruction; urethral stent; or injection for stricture occuring. 328 men had no prior history of urinary obstruction prior to cryotherapy.

Erectile Dysfunction included medical claim for penile prosthesis or intracavernosal. 349 men had no Prior history of erectile dysfunction prior to cryotherapy.

Urinary incontinence included a medical claim of urethra sphincter injection, artificial sphincter, or incontinence repair (sling, urethroplasty) occuring. 368 men had no prior history of urinary incontinence prior to cryotherapy.

Bowel bleeding included hemorrhage or inflammation. 359 men did not have bowel bleeding prior to cryotherapy.

Hydronephrosis is distention of the renal pelvic and calices of the kidney with urine.

Bowel Fistula included medical claims of rectal repair, colostomy or ulcer.

Urinary Fistula was defined as medical claims with repair of bowel-bladder fistula or closure of urethrostomy or urethrocutaneous fistula occurring.

###### 

Medical codes regarding diagnoses and corrective invasive procedures for complications occurring after cryotherapy as initial treatment for prostate cancer

Definitions of complications following cryotherapy.

                                                                            Medical Codes                                                                                                         
  ------------------------------------------------------------------------- ----------------------------- --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  **Erectile**                                                                                                                                                                                    
      Impotence, dysfunction                                                607.84                                                                                                                
      Penile Prosthesis                                                                                   64.94, 64.95, 64.96, 64.97                                                              54400, 54401, 54402, 54405, 54407, 54408, 54409, 54410, 54411, 54415, 54416, 54417, C1007, C1813, C2622, C3500, C8514, C8516, C8534, L7900
      Intracavernosal injection                                                                                                                                                                   54231, 54235, J0270, J0275, J2440, J2760
  **Lower Urinary Tract Obstruction**                                                                                                                                                             
      Stricture, obstruction, retention                                     596.0, 598.x, 599.6, 788.2x                                                                                           
      Dilation, urethrotomy, urethroplasty, sphincterotomy                                                57.85, 57.91, 57.92, 58.0, 58.1, 58.3x, 58.44, 58.46, 58.47, 58.5, 58.6, 58.99, 60.95   52275, 52276, 52281,52510, 53010, 53400, 53405,53410, 53415, 53420, 53425, 53600, 53601, 53605, 53620, 53621
      Transurethral prostate resection/destruction                                                        60.2x                                                                                   52601, 52612, 52614, 52620, 52630, 53850, 53852
      Urethral Stent                                                                                                                                                                              2282
      Injection for Stricture                                                                                                                                                                     52283
  **Urinary Incontinence**                                                                                                                                                                        
      Incontinence, sphincter, deficiency                                   788.3x, 599.82                                                                                                        
      Urethra, sphincter injection                                                                        59.72                                                                                   51715
      Artificial sphincter                                                                                58.93                                                                                   53445, 53447
      Incontinence repair (sling, urethroplasty)                                                          59.3, 59.4, 59.5, 59.6, 59.71, 59.79                                                    53440, 51840, 51841, 53442, 53443
  **Urinary Fistula**                                                       596.1, 596.2, 599.1           57.83, 57.84, 58.43                                                                     44660, 44661, 53520
      Urethral fistula                                                      5991                                                                                                                  
      Intestinovesical fistula                                              5961                                                                                                                  
      Vesical fistula NEC                                                   5962                                                                                                                  
      Repair of a bowel-bladder fistula or closure of urethrostomy                                        5783, 5784, 5843                                                                        44660, 44661, 53520
  **Bowel Fistula**                                                                                                                                                                               
      Fistula, ulcer                                                        569.41, 569.81                48.73, 48.93                                                                            45800, 45805, 45820, 45825
      Rectal repair, colostomy                                                                            46.1x, 48.31, 48.32, 48.33                                                              45562, 45563
  **Hydronephrosis**                                                                                                                                                                              
      Distention of the renal pelvic and calices of the kidney with urine   591                                                                                                                   
  **Bowel Bleeding**                                                                                                                                                                              
      Hemorrhage, inflammation                                              558.1, 569.3, 578.9                                                                                                   

ICD-9-CM = International Classification of Diseases, 9th revision, Clinical Modification

CPT = Current Procedural Terminology

HCPCS = Health Care Financing Administration Common Procedure Coding System
